Pharmaron Beijing Co Ltd - Asset Resilience Ratio
Pharmaron Beijing Co Ltd (300759) has an Asset Resilience Ratio of 4.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Pharmaron Beijing Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Pharmaron Beijing Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.08 Billion | 4.17% |
| Total Liquid Assets | CN¥1.08 Billion | 4.17% |
Asset Resilience Insights
- Limited Liquidity: Pharmaron Beijing Co Ltd maintains only 4.17% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pharmaron Beijing Co Ltd Industry Peers by Asset Resilience Ratio
Compare Pharmaron Beijing Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
Annual Asset Resilience Ratio for Pharmaron Beijing Co Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Pharmaron Beijing Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.66% | CN¥1.12 Billion | CN¥23.93 Billion | +2.42pp |
| 2023-12-31 | 2.24% | CN¥594.33 Million | CN¥26.48 Billion | -1.39pp |
| 2022-12-31 | 3.64% | CN¥745.36 Million | CN¥20.49 Billion | -4.82pp |
| 2021-12-31 | 8.45% | CN¥1.55 Billion | CN¥18.39 Billion | +0.81pp |
| 2020-12-31 | 7.64% | CN¥910.01 Million | CN¥11.91 Billion | +5.79pp |
| 2019-12-31 | 1.85% | CN¥183.45 Million | CN¥9.94 Billion | +1.84pp |
| 2018-12-31 | 0.01% | CN¥412.62K | CN¥4.63 Billion | -- |
About Pharmaron Beijing Co Ltd
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more